119 related articles for article (PubMed ID: 7707164)
21. Self-measurement of blood pressure at home to evaluate drug effects by the trough: peak ratio.
Ménard J; Chatellier G; Day M; Vaur L
J Hypertens Suppl; 1994 Nov; 12(8):S21-5. PubMed ID: 7707151
[TBL] [Abstract][Full Text] [Related]
22. Balanced 24-hour blood pressure control by angiotensin-converting enzyme inhibitors administered once daily.
Parati G; Ravogli A; Trazzi S; Omboni S; Frattola A; Lattuada S; Libretti A; Mancia G
J Hum Hypertens; 1989 Jun; 3 Suppl 1():3-9. PubMed ID: 2674440
[TBL] [Abstract][Full Text] [Related]
23. Trough and peak effects of a single daily dose of nifedipine gastrointestinal therapeutic system (GITS) as assessed by ambulatory blood pressure monitoring. Italian Nifedipine GITS Study Group.
Zanchetti A
J Hypertens Suppl; 1994 Jul; 12(5):S23-7. PubMed ID: 7965282
[TBL] [Abstract][Full Text] [Related]
24. Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition.
Hingorani AD; Jia H; Stevens PA; Hopper R; Dickerson JE; Brown MJ
J Hypertens; 1995 Dec; 13(12 Pt 2):1602-9. PubMed ID: 8903618
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs.
King JN; Mauron C; Kaiser G
Am J Vet Res; 1995 Dec; 56(12):1620-8. PubMed ID: 8599524
[TBL] [Abstract][Full Text] [Related]
26. Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease.
Brugts JJ; Ferrari R; Simoons ML
Expert Rev Cardiovasc Ther; 2009 Apr; 7(4):345-60. PubMed ID: 19379059
[TBL] [Abstract][Full Text] [Related]
27. [Do converting enzyme inhibitors differ from each other in the treatment of hypertension?].
Laurent S; Billaud E; Kreft-Jais C
Rev Prat; 1992 Dec; 42(20):2533-7. PubMed ID: 1299936
[TBL] [Abstract][Full Text] [Related]
28. The trough-to-peak ratio as an instrument to evaluate antihypertensive drugs. The APTH Investigators. Ambulatory Blood Pressure and Treatment of Hypertension Trial.
Staessen JA; Bieniaszewski L; Buntinx F; Celis H; O'Brien ET; van Hoof R; Fagard R
Hypertension; 1995 Dec; 26(6 Pt 1):942-9. PubMed ID: 7490153
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of enalapril and lisinopril in subjects with normal and impaired hepatic function.
Hayes PC; Plevris JN; Bouchier IA
J Hum Hypertens; 1989 Jun; 3 Suppl 1():153-8. PubMed ID: 2550638
[TBL] [Abstract][Full Text] [Related]
30. Overview of the angiotensin-converting-enzyme inhibitors.
Piepho RW
Am J Health Syst Pharm; 2000 Oct; 57 Suppl 1():S3-7. PubMed ID: 11030016
[TBL] [Abstract][Full Text] [Related]
31. The effect of cilazapril, a new angiotensin converting enzyme inhibitor, on peak and trough blood pressure measurements in hypertensive patients.
Güntzel P; Kobrin I; Pasquier C; Zimlichman R; Viskoper JR
J Cardiovasc Pharmacol; 1991 Jan; 17(1):8-12. PubMed ID: 1708060
[TBL] [Abstract][Full Text] [Related]
32. Modulation of acute transient exercise-induced hypertension after oral administration of four angiotensin-converting enzyme inhibitors in normotensive horses.
Muñoz A; Esgueva M; Gómez-Díez M; Serrano-Caballero JM; Castejón-Riber C; Serrano-Rodríguez JM
Vet J; 2016 Feb; 208():33-7. PubMed ID: 26626097
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of high through-to-peak ratio of perindopril in SHR.
Moriyama S; Ishigai Y; Mori T; Fukuzawa A; Shibano T
Clin Exp Hypertens; 1999 Oct; 21(7):1223-38. PubMed ID: 10513838
[TBL] [Abstract][Full Text] [Related]
34. Trandolapril. How does it differ from other angiotensin converting enzyme inhibitors?
Zannad F
Drugs; 1993; 46 Suppl 2():172-81; discussion 182. PubMed ID: 7512472
[TBL] [Abstract][Full Text] [Related]
35. Newer ACE inhibitors. A look at the future.
Salvetti A
Drugs; 1990 Dec; 40(6):800-28. PubMed ID: 2078997
[TBL] [Abstract][Full Text] [Related]
36. Trough to peak ratio of once-daily lisinopril and twice-daily captopril in patients with essential hypertension.
Martell N; Gill B; Marin R; Suarez C; Tovar JL; Cia P; Fernandez C; Gonzalez L; Maldonado A; Fernández F; del Arco C; Garcia I; Yuste I; Luque M
J Hum Hypertens; 1998 Jan; 12(1):69-72. PubMed ID: 9482137
[TBL] [Abstract][Full Text] [Related]
37. Choosing the right ACE inhibitor. A guide to selection.
Leonetti G; Cuspidi C
Drugs; 1995 Apr; 49(4):516-35. PubMed ID: 7789286
[TBL] [Abstract][Full Text] [Related]
38. Effect of dose on trough peak ratio of antihypertensive drugs in elderly hypertensive males.
Morgan TO; Morgan O; Anderson A
Clin Exp Pharmacol Physiol; 1995 Oct; 22(10):778-80. PubMed ID: 8575118
[TBL] [Abstract][Full Text] [Related]
39. Trough:peak ratio of the blood pressure response to beta-blockers.
Wing LM
J Hypertens Suppl; 1994 Nov; 12(8):S85-90. PubMed ID: 7707162
[TBL] [Abstract][Full Text] [Related]
40. Duration of action of angiotensin converting enzyme inhibitors.
Zannad F
Am J Hypertens; 1995 Oct; 8(10 Pt 2):75S-81S. PubMed ID: 8845089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
